| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/02/2002 | CN1328851A Medicine for curing rheumatic heart disease |
| 01/02/2002 | CN1077103C Chiral methyl phenyl oxazolidinones |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335358 Lactacystin analogs |
| 01/01/2002 | US6335352 Administering heterocyclic cyanoguanidine derivatives as chemokine inhibitors |
| 01/01/2002 | US6335349 Agents that reduce levels of tumor necrosis factor; anticarcinogenic and antiinflammatory agents; treatment of autoimmune diseases |
| 01/01/2002 | US6335340 compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses |
| 01/01/2002 | US6335338 Calcilytic compounds |
| 01/01/2002 | US6335333 Matrix metalloproteinase inhibitors |
| 01/01/2002 | US6335332 Barbituric acid derivatives with antimetastatic and antitumor activity |
| 01/01/2002 | US6335329 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 01/01/2002 | US6335039 Pharmaceutical formulations comprising vegetal material selected from trichilia |
| 01/01/2002 | US6335023 Vehicles and oligosaccharide aldonic acids |
| 01/01/2002 | CA2093789C Bi-aromatic compounds and their use in human and veterinary medicine and in cosmetic preparations |
| 01/01/2002 | CA2056799C 1,4-dihydropyridine derivatives and methods of producing the same |
| 01/01/2002 | CA2042473C Piperidino-nmda antagonists |
| 12/29/2001 | CA2351904A1 Target |
| 12/27/2001 | WO2001098508A2 Transgenic mice containing targeted gene disruptions |
| 12/27/2001 | WO2001098493A1 Insulin-like growth factor-binding protein |
| 12/27/2001 | WO2001098471A2 Human phosphodiesterases |
| 12/27/2001 | WO2001098468A2 Proteases |
| 12/27/2001 | WO2001098365A2 Peptide and polypeptide inhibitors of complement c1s |
| 12/27/2001 | WO2001098357A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | WO2001098354A2 Human receptors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098344A2 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098330A2 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | WO2001098290A2 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 12/27/2001 | WO2001098289A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | WO2001098278A1 Methods and compositions utilizing quinazolinones |
| 12/27/2001 | WO2001098273A1 Novel compounds |
| 12/27/2001 | WO2001098272A1 Novel compounds |
| 12/27/2001 | WO2001098270A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098269A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098268A2 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098262A1 Amidine derivatives as selective antagonists of nmda receptors |
| 12/27/2001 | WO2001098253A2 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists |
| 12/27/2001 | WO2001097872A1 Bioadhesive compositions and methods of preparation and use |
| 12/27/2001 | WO2001097860A2 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 12/27/2001 | WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097813A2 Highly concentrated stable meloxicam solutions |
| 12/27/2001 | WO2001097795A2 Systems and methods for treating a mucosal surface |
| 12/27/2001 | WO2001097775A2 Controlled release anti-inflammatory formulation |
| 12/27/2001 | WO2001085719A9 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 12/27/2001 | WO2001064659A3 Indane derivatives and their use as cell adhesion inhibitors |
| 12/27/2001 | WO2001062223A3 Cosmetic preparations containing plant extracts |
| 12/27/2001 | WO2001060349B1 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof. |
| 12/27/2001 | WO2001057042A3 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001046256A3 Vesicle trafficking proteins |
| 12/27/2001 | WO2001045650A3 Cosmetic use of the residues from wine production |
| 12/27/2001 | WO2001037782A3 Method and composition for the treatment of scars |
| 12/27/2001 | WO2001023390A3 Azepinoindole derivatives, the production and use thereof |
| 12/27/2001 | WO2000067626A3 Oat extracts: refining, compositions and methods of use |
| 12/27/2001 | WO2000064485A3 Specifically targeted catalytic antagonists and uses thereof |
| 12/27/2001 | WO2000055109A9 Lipoxin compounds and their use |
| 12/27/2001 | US20010056184 Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds |
| 12/27/2001 | US20010056183 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 12/27/2001 | US20010056118 Induction of polymerization of tubulin and the stabilization of microtubules in cells by administering to the cancer cells an effective amount of dictyostatin-1 or derivatives or salt |
| 12/27/2001 | US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12 |
| 12/27/2001 | US20010056110 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
| 12/27/2001 | US20010056107 Cyano and carboxy derivatives of substituted styrenes are inhibitors of tumor necrosis factor alpha , nuclear factor kappa B, and phosphodiesterase and can be used to treat cachexia, endotoxic shock, inflammatory conditions etc. |
| 12/27/2001 | US20010056100 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 12/27/2001 | US20010056092 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 12/27/2001 | US20010056069 Use of collagen for the treatment of degenerative articular processes |
| 12/27/2001 | US20010055569 Nasal drug delivery composition |
| 12/27/2001 | CA2414085A1 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 12/27/2001 | CA2414015A1 Human receptors |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |
| 12/27/2001 | CA2413878A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | CA2413866A1 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | CA2413830A1 Peptide and polypeptide inhibitors of complement c1s |
| 12/27/2001 | CA2413435A1 A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists |
| 12/27/2001 | CA2413421A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | CA2413418A1 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | CA2413328A1 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 12/27/2001 | CA2413274A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | CA2412484A1 G-protein coupled receptors |
| 12/27/2001 | CA2412215A1 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | CA2411978A1 Transgenic mice containing targeted gene disruptions |
| 12/27/2001 | CA2411971A1 Proteases |
| 12/27/2001 | CA2411585A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | CA2411255A1 Novel compounds |
| 12/27/2001 | CA2411236A1 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | CA2410632A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | CA2410208A1 Systems and methods for treating a mucosal surface |
| 12/27/2001 | CA2409781A1 Phosphodiesterases |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/26/2001 | CN1328571A Human monoclonal antibodies to CTLA-4 |
| 12/26/2001 | CN1328550A Oxazole compounds as prostaglandin E2 agonists or antagonists |
| 12/26/2001 | CN1328545A Hydrazine derivatives |
| 12/26/2001 | CN1328454A Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 12/26/2001 | CN1328450A Particles coated with granulated crystalline ibuprofen |
| 12/26/2001 | CN1328447A Process for producing particles with converted amorphous and/or meta-stable crystalline region into crystalline state |